INTRODUCTION {#Sec1}
============

Understanding the risks associated with the COVID-19 pandemic^[@CR1]^ on healthcare workers (HCW), including the risk of acquisition at work vs. other settings, is crucial. Prediction of risk can inform how to protect HCW such as recommendations on use of personal protective equipment (PPE) at work or in the community. The presence of specific symptoms in HCW (China, USA)^[@CR2],\ [@CR3]^ and symptoms predicting SARS-CoV-2 test positivity in HCW (Netherlands)^[@CR4]^ has been reported as well as characteristics associated with HCW deaths (China).^[@CR5]^ Based upon data from the 2018 National Health Interview Survey, it was estimated that 26.6% of patient-facing HCW were at increased risk for poor outcomes from COVID-19 infection because of their comorbidities or age.^[@CR6]^ Reported experiences in China,^[@CR7]^ Italy,^[@CR8]^ and Solano County, CA, without initial use of PPE,^[@CR9]^ showed higher percentages of HCW testing positive for COVID-19. In contrast, a screening study of HCW in England showed no significant difference in positive results between clinical and nonclinical staff with implementation of isolation and PPE protocols perhaps suggesting predominant community rather than nosocomial transmission patterns.^[@CR10]^ The extent of risk modification with PPE remains unclear. ^[@CR7]--[@CR9],\ [@CR11]^ A recent prospective study in the UK and USA suggested a fivefold increased risk for HCW caring for patients with COVID-19 compared to HCW not caring for patients with COVID-19, even with the use of PPE,^[@CR12]^ while another study of HCW in a large healthcare system showed a decrease in positive tests for SARS-CoV-2 associated with a universal masking recommendation.^[@CR13]^ This heterogeneous landscape makes it difficult for the HCW community to determine actual risk of acquiring COVID-19 in healthcare vs. community settings and the effectiveness of various risk-mitigating strategies.

The Cleveland Clinic Health System (CCHS) is a large, integrated health system with 55,574 eligible employees in Ohio and Florida. The CCHS initiated multiple COVID-19-related public health initiatives to mitigate the spread of the disease and its impact on the HCW community. In parallel, we maintained a rigorous, comprehensive, and prospective registry capturing disease risk and progression in all individuals tested for COVID-19 in our health system. In this study, we aimed to assess whether HCW are at higher risk for COVID-19 infection, COVID-19-related hospitalization, and intensive care unit (ICU) admission compared to non-HCW using advanced statistical methodology to account for various confounders.

METHODS {#Sec2}
=======

Cohort Definition {#Sec3}
-----------------

### COVID-19 Cleveland Clinic enterprise registry {#FPar1}

All patients, regardless of age, who were tested for COVID-19 at all CCHS locations in Ohio and Florida, were included in this research registry. For this study, all individuals who were tested for COVID-19 in the CCHS between March 8, 2020, and June 9, 2020, were studied. This registry provides better representation of the overall population than testing restricted to one geographic health system site. Registry variables were chosen to reflect available literature on COVID-19 disease characterization, progression, and proposed treatments, including medications initially thought to have potential for benefit after drug-repurposing network analysis.^[@CR14]^ Capture of detailed research data was facilitated by the creation of standardized clinical templates implemented across the healthcare system as patients were seeking care for COVID-19-related concerns. Data were extracted via previously validated automated feeds from electronic health records^[@CR15]^ (EPIC; EPIC Systems Corporation) and manually by a study team trained on uniform sources for the study variables. Study data were collected and managed using REDCap electronic data capture tools hosted at the Cleveland Clinic.^[@CR16],\ [@CR17]^ The COVID-19 Research Registry team includes a "Reviewer" group and a "Quality Assurance" group. The reviewers were responsible for manually abstracting and entering a subset of variables that cannot be automatically extracted from the electronic health record (EHR). Reviewers were also asked to verify high-priority variables that have been automatically pulled into the database from EPIC. The Cleveland Clinic Institutional Review Board approved this study and waived the requirements for written informed consent.

### Identification of HCW {#FPar2}

Individuals were identified as HCW through the CCHS Occupational Health, and their job description was identified as having direct contact with patients or "patient facing" vs. non-patient facing based upon the listing in the CCHS Human Resources database.

Public Health and Employer-Initiated Risk-Mitigation Measures {#Sec4}
-------------------------------------------------------------

Public health guidelines for CCHS employees and availability of testing for COVID-19 changed rapidly between March 6, 2020, and April 24, 2020 (Appendix [1](#MOESM1){ref-type="media"}), the most relevant being the *recommendation* for universal masking for CCHS employees on April 7, 2020, and *requirement* on April 24, 2020. Regarding state public health orders, a stay-at-home order was issued in Ohio on March 22, 2020, with phased reopening in May starting with restaurants and bars on May 14, 2020,^[@CR18]^ and in Florida, a public health advisory was issued on March 25, 2020, addressing vulnerable populations, private gatherings, and workforce density^[@CR19]^ with reopening beginning on May 18, 2020.^[@CR20]^

Statistical Analysis {#Sec5}
--------------------

All descriptive statistics were reported as counts (percentages) or median (interquartile ranges \[IQRs\]). For comparison of demographic variables and comorbidities among cohorts, Wilcoxon signed-rank tests were used for numeric variables, while *χ*^2^ or Fisher exact tests were used for categorical variables. To address differences in baseline characteristics of non-HCW and HCW, specifically as related to underlying comorbidities, and the limitations of current literature that failed to account for such differences, we leveraged appropriate statistical methodology to study our research questions. Overlap propensity score^[@CR21],\ [@CR22]^ weighting was performed to address potential confounding in comparing HCW to non-HCW given their baseline differences. The overlap propensity score weighting method was chosen given its benefits of preservation of numbers of individuals in each group and of achieving higher levels of precision in the resulting estimates. This methodology is preferred when the propensity score distributions among the groups are dissimilar and when the propensity scores are clustered near the extremes (i.e., close to zero or one). A propensity score for being a HCW was estimated from a multivariable logistic regression model. For the outcome of being test positive for COVID-19, the propensity score logistic regression model included covariates that were found to be associated with a positive COVID-19 test outcome in our previous work.^[@CR23]^ For the outcomes of hospital and intensive care unit (ICU) admission of COVID-19 test-positive patients, the propensity score covariates are those that were found associated with COVID-19 hospitalization outcome in our previous work including age, race, ethnicity, gender, smoking history, body mass index, median income, population per housing unit, presenting symptoms (including fever, fatigue, shortness of breath, diarrhea, vomiting), comorbidities (including asthma, hypertension, diabetes, immunosuppressive disease), medications (including immunosuppressive treatment, nonsteroidal anti-inflammatory drugs \[NSAIDs\]), and laboratory values (including pre-testing platelets, aspartate aminotransferase, blood urea nitrogen, chloride, and potassium).

The overlap propensity score weighting method was then applied where each patient's statistical weight is the probability of that patient being assigned to the opposite group.^[@CR21]^ Overlap propensity score weighted logistic regression models were used to investigate associations between HCW status and the probability of testing positive for SARS-CoV-2, hospital admission for COVID-19, and ICU admission for COVID-19 illness. The results are thus reported as weighted proportions, odds ratios, and 95% confidence intervals. All statistical analyses were performed using R 3.5 and SAS version 9.4 (SAS Institute). *P* values were 2-sided, with a significance threshold of 0.05.

We then used locally weighted regression smoother (LOESS) to summarize the trend of COVID-19 test positivity through the study period for HCW and non-HCW as related to the public health measures instituted at the state level and those specific to the CCHS.

RESULTS {#Sec6}
=======

Overall tested cohort characteristics {#FPar3}
-------------------------------------

Of the 72,909 individuals tested for COVID-19 in the CCHS Research Registry, there were 6145 HCW and 66,764 non-HCW with over 90% of HCW and 75% of non-HCW tested from Ohio. There were 9% of HCW who tested positive for COVID-19 compared to 6.5% of non-HCW, *p* \< 0.001 (Table [1](#Tab1){ref-type="table"}). The HCW tested were younger than the non-HCW (median age 39.7 vs. 57.5, *p* \< 0.001) with more females (proportion of males 21.5 vs. 44.9%, *p* \< 0.001), higher proportion of Asian and lower proportion of Black persons (3.4 vs. 1.0% and 16.2 vs. 18.3%, respectively, *p* \< 0.001), higher proportion identifying as non-Hispanic (90.8 vs. 87.6%, *p* \< 0.001), higher median income, and higher proportion of nonsmokers. The neighborhood characteristic of population density as measured per square kilometer was similar for tested HCW vs. non-HCW while the population per housing unit was slightly higher. The HCW were more likely to report an exposure to COVID-19 (72.0% vs. 17.0%, *p* \< 0.001) and also to report having a family member with COVID-19 (28.3 vs. 14.2%, *p* 0.005). Regarding presenting symptoms, a slightly higher proportion of HCW reported cough (32.0 vs. 29.6%, *p* 0.001), a lower proportion reported fever (15.0 vs. 19.5%, *p* \< 0.001) or shortness of breath (14.6 vs. 25.7%, *p* \< 0.001), while a higher proportion reported diarrhea (11.9 vs. 9.5%, *p* \< 0.001) and a lower proportion reported vomiting (7.4 vs. 9.7%, *p* \< 0.001). Of note, the tested HCW were, in general, healthier than the non-HCW group. The HCW had a lower proportion of several comorbidities including chronic obstructive pulmonary disease(COPD)/emphysema, diabetes, hypertension, coronary artery disease, heart failure, cancer, history of transplant, or immunosuppressive disease and were more likely to have received the influenza vaccine (85.9 vs. 45.4%, *p* \< 0.001). The HCW tested had a lower proportion of previous prescriptions for immunosuppressive treatment, NSAIDs, steroids, carvedilol, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or melatonin.Table 1Characteristics of All Patients Tested for SARS-CoV-2 by Healthcare Worker (HCW) StatusNon-HCW\
Number (%) or median \[interquartile range\]HCW\
Number (%) or median \[interquartile range\]*p* valueNumber66,7646145SARS-CoV-2 positive4353 (6.5)551 (9.0)\< 0.001Demographics  Location\< 0.001   Ohio50,204 (75.2)5642 (91.8)   Florida13,957 (20.9)503 (8.2)   Unknown2603 (3.9)0  Race\< 0.001   Asian672 (1.0)206 (3.4)   Black12,201 (18.3)995 (16.2)   Other5394 (8.1)490 (8.0)   White48,497 (72.6)4454 (72.5)  Male29,959 (44.9)1322 (21.5)\< 0.001  Non-Hispanic58,496 (87.6)5577 (90.8)\< 0.001  Smoking\< 0.001   Current smoker9316 (14.0)147 (2.4)   Former smoker30,196 (45.2)1737 (28.3)   No27,048 (40.5)4259 (69.3)   Unknown204 (0.3)2 (0.0)  Age57.53 \[39.32, 70.26\]39.67 \[31.29, 51.80\]\< 0.001Exposure history  Exposed to COVID-1911,369 (17.0)4424 (72.0)\< 0.001  Family member with COVID-199503 (14.2)1740 (28.3)\< 0.001Presenting symptoms  Cough19,744 (29.6)1968 (32.0)0.001  Fever12,997 (19.5)922 (15.0)\< 0.001  Fatigue8020 (12.0)637 (10.4)\< 0.001  Sputum production402 (0.6)45 (0.7)0.244  Flu-like symptoms5949 (8.9)423 (6.9)\< 0.001  Shortness of breath17,133 (25.7)898 (14.6)\< 0.001  Diarrhea6335 (9.5)731 (11.9)\< 0.001  Loss of appetite1505 (2.3)299 (4.9)\< 0.001  Vomiting6471 (9.7)454 (7.4)\< 0.001Comorbidities  Body mass index28.37 \[25.85, 31.07\]28.37 \[27.37, 29.13\]\< 0.001  Chronic obstructive pulmonary disease/emphysema8247 (12.4)166 (2.7)\< 0.001  Asthma12,057 (18.1)1343 (21.9)\< 0.001  Diabetes13,418 (20.1)428 (7.0)\< 0.001  Hypertension30,727 (46.0)1505 (24.5)\< 0.001  Coronary artery disease10,181 (15.2)204 (3.3)\< 0.001  Heart failure8192 (12.3)93 (1.5)\< 0.001  Cancer12,469 (18.7)646 (10.5)\< 0.001  Transplant history1120 (1.7)19 (0.3)\< 0.001  Multiple sclerosis493 (0.7)43 (0.7)0.794  Connective tissue disease2376 (3.6)178 (2.9)0.008  Inflammatory bowel disease1604 (2.4)112 (1.8)0.005  Immunosuppressive disease10,375 (15.5)414 (6.7)\< 0.001Vaccination history  Influenza vaccine30,340 (45.4)5277 (85.9)\< 0.001  Pneumococcal polysaccharide vaccine17,808 (26.7)451 (7.3)\< 0.001Laboratory findings upon presentation  Pre-testing platelets238.00 \[238.00, 238.00\]238.00 \[238.00, 238.00\]0.137  Pre-testing AST23.00 \[23.00, 23.00\]23.00 \[23.00, 23.00\]0.051  Pre-testing BUN16.00 \[16.00, 16.00\]16.00 \[16.00, 16.00\]\< 0.001  Pre-testing chloride101.00 \[101.00, 101.00\]101.00 \[101.00, 101.00\]0.092  Pre-testing creatinine0.92 \[0.92, 0.92\]0.92 \[0.92, 0.92\]\< 0.001  Pre-testing hematocrit39.50 \[39.50, 39.50\]39.50 \[39.50, 39.50\]0.41  Pre-testing potassium4.10 \[4.10, 4.10\]4.10 \[4.10, 4.10\]0.081Home medications  Immunosuppressive treatment2392 (3.6)270 (4.4)\< 0.001  Nonsteroidal anti-inflammatory drugs19,651 (29.4)1048 (17.1)\< 0.001  Steroids11,838 (17.7)969 (15.8)\< 0.001  Carvedilol2803 (4.2)40 (0.7)\< 0.001  Angiotensin-converting enzyme inhibitor7568 (11.3)329 (5.4)\< 0.001  Angiotensin receptor blocker5698 (8.5)228 (3.7)\< 0.001  Melatonin3078 (4.6)52 (0.8)\< 0.001Social influencers of health  Population per km^2^3.03 \[2.63, 3.29\]3.01 \[2.64, 3.28\]0.568  Median income per \$100058.09 \[41.62, 76.21\]64.78 \[49.78, 85.54\]\< 0.001  Population per housing unit2.22 \[1.93, 2.49\]2.26 \[2.01, 2.51\]\< 0.001

COVID-19 cohort characteristics and outcomes {#FPar4}
--------------------------------------------

There were 551 HCW and 4353 non-HCW who tested positive for COVID-19 (Appendix Table [1](#MOESM1){ref-type="media"}). Of those who tested positive for COVID-19, a lower proportion of HCW were hospitalized compared to non-HCW (38 or 6.9% HCW vs. 1205 or 27.7% non-HCW) or were admitted to the intensive care unit (10 or 1.8% HCW vs. 470 or 10.8% non-HCW). In the group who tested positive for COVID-19, there was a greater proportion of HCW of Asian and White race compared to non-HCW (2.9 vs. 0.8% and 61.0 vs 56.4%, respectively); a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting; and a lower proportion had fever or shortness of breath. Lower proportions of HCW testing positive had COPD/emphysema, diabetes, coronary artery disease, heart failure, cancer, or immunosuppressive disease and were previously prescribed carvedilol, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or melatonin compared to non-HCW. The neighborhood population characteristics of population density or population per housing unit did not differ for those HCW who tested positive and median income was slightly higher compared to non-HCW.

Overlap propensity weighting {#FPar5}
----------------------------

Using the variables in the prediction model for COVID-19 test positivity,^[@CR23]^ overlap propensity score weighting (Table [2](#Tab2){ref-type="table"}) resulted in propensity score weighted proportions of 7.7 vs. 8.9 for non-HCW vs. HCW having a positive test and produced an overlap propensity score weighted odds ratio of 1.17 with a 95% confidence interval (CI) of 0.99--1.38 for a HCW having a positive test compared to a non-HCW (Fig. [1a](#Fig1){ref-type="fig"}). Then using the variables which predicted hospitalization for COVID-19 infection, overlap propensity score weighting was applied (Table [3](#Tab3){ref-type="table"}) with weighted proportions for being hospitalized 15.9 vs. 7.4 for non-HCW vs. HCW, an odds ratio of 0.42 (CI 0.26--0.66) for a HCW being hospitalized for COVID-19 compared to a non-HCW. For ICU admission, weighted proportions were 4.5 vs. 2.2 for non-HCW vs. HCW with an odds ratio of 0.48 (CI 0.20--1.04) for HCW being admitted to the ICU compared to non-HCW (Fig. [1a](#Fig1){ref-type="fig"}).Table 2All Tested Patients: Overlap Propensity Score-Weighted CharacteristicsNon-HCWHCWCount66,7646145Race  Asian2.32.3  Black17.917.9  Other88  White71.871.8Male25.125.1Non-Hispanic90.290.2Smoking  Current smoker3.73.7  Former smoker31.731.7  No64.664.6  Unknown00Age43.3843.38Exposed to COVID-1958.158.1Family member with COVID-190.10.1Cough34.434.4Fever1818Fatigue11.711.7Sputum production0.90.9Flu-like symptoms7.37.3Diarrhea12.712.7Loss of appetite4.34.3Vomiting8.78.7Asthma22.922.9Coronary artery disease4.64.6Transplant history0.50.5Connective tissue disease3.43.4Inflammatory bowel disease2.12.1Influenza vaccine79.279.2Pneumococcal polysaccharide vaccine11.311.3Pre-testing platelets240.05240.05Pre-testing aspartate aminotransferase23.8723.87Pre-testing chloride101.05101.05Pre-testing creatinine0.920.92Pre-testing hematocrit39.4839.48Pre-testing potassium4.094.09Nonsteroidal anti-inflammatory drugs20.420.4Steroids17.417.4Carvedilol0.90.9Angiotensin-converting enzyme inhibitor6.76.7Angiotensin receptor blocker4.94.9Melatonin1.21.2Population per km^2^2.922.92Median income (thousands of dollars)68.2068.20Body mass index2.922.92*Final result = positive test for SARS-CoV-2*7.78.9*Odds ratio (95% confidence interval)*1.17 (0.99, 1.38)Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)Figure 1**a Odds of SARS-CoV-2 positive test; hospital admission if SARS-CoV-2 positive and intensive care admission if SARS-CoV-2 positive by healthcare worker (HCW) status. b Odds of SARS-CoV-2 positive test; hospital admission if SARS-CoV-2 positive and intensive care admission if SARS-CoV-2 positive by patient-facing and non-patient-facing healthcare worker status. OR = odds ratio, LCL = lower confidence limit, UCL = upper confidence limit.**Table 3All Test Positive Patients: Overlap Propensity Score-Weighted CharacteristicsNon-HCWHCWCount4353551Race  Asian2.12.1  Black28.628.6  Other9.49.4  White59.959.9Male30.730.7Ethnicity  Hispanic3.33.3  Non-Hispanic90.290.2  Unknown6.46.4Smoking  Current smoker2.92.9  Former smoker18.618.6  No73.773.7  Unknown4.84.8Age43.5043.50Fever44.844.8Fatigue55.255.2Shortness of breath3737Diarrhea3535Vomiting24.724.7Asthma12.612.6Diabetes10.410.4Hypertension22.222.2Immunosuppressive treatment6.96.9Immunosuppressive disease4.54.5Pre-testing platelets234.70234.70Pre-testing aspartate aminotransferase24.5124.51Pre-testing blood urea nitrogen15.7615.76Pre-testing chloride100.04100.04Pre-testing potassium3.993.99Nonsteroidal anti-inflammatory drugs17.417.4Median income (thousands of dollars)62.2562.25Population per housing unit2.222.22Body mass index29.6329.63*Final result = hospitalization*15.97.4*Odds ratio (95% confidence interval)*0.42 (0.26, 0.66)*Intensive care unit admission*4.52.2*Odds ratio (95% confidence interval)*0.48 (0.20, 1.04)Reported are either weighted proportions (for categorical variables) or weighted means (for numeric variables)

Subgroup Analysis {#Sec7}
-----------------

We then compared characteristics of HCW identified as having positions that required direct contact with patients ("patient facing") and those that did not. There were 5159 HCW with patient-facing positions and 986 HCW in non-patient-facing roles (Appendix Table [3](#MOESM1){ref-type="media"}). The HCW with patient-facing roles were younger (median age 38 vs. 47 years, *p* \< 0.001), with more females (proportion males 20.6 vs. 26.2%, *p* \< 0.001), lower proportion of Black race and higher Asian race, and with greater proportion reporting exposure to COVID-19 (73.7 vs. 62.9%, *p* \< 0.001). The patient-facing HCW had lower proportions presenting with fatigue or shortness of breath and higher proportion with loss of appetite. There were no significant differences in laboratory values upon presentation. The patient-facing HCW had lower proportions of some previously prescribed medications including NSAIDs, steroids, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and melatonin. The patient-facing HCW group had lower proportions of comorbidities including COPD/emphysema, diabetes, hypertension, coronary artery disease, cancer, connective tissue disease, and immunosuppressive disease. Applying the overlap propensity score weighting (Appendix Tables [4 and 5](#MOESM1){ref-type="media"}; Fig. [1b](#Fig1){ref-type="fig"}) showed patient-facing HCW with increased odds of having a positive SARS-CoV-2 test result (OR 1.60, CI 1.08--2.39, weighted proportions 8.6 vs. 5.5), and lower but nonsignificant odds of hospital admission (OR 0.88, CI 0.20--3.66, proportions 10.2 vs. 11.4) and ICU admission (OR 0.34, CI 0.01--3.97, proportions 1.8 vs. 5.2).

Temporal Relationship between Disease Prevention Measures and Positive Tests {#Sec8}
----------------------------------------------------------------------------

The summary of the trend of SARS-CoV-2 positive test results in the study period is shown in Figure [2](#Fig2){ref-type="fig"}. The overall proportion of positive COVID-19 test results decreased during the study period and the trend for HCW and followed that of non-HCW.Figure 2**Proportion of SARS-CoV-2 positive results during the study period. CCHS = Cleveland Clinic Health System.**

DISCUSSION {#Sec9}
==========

Our analysis of HCW compared to non-HCW who were tested for SARS-CoV-2 in one health system with 2 geographic locations (Ohio, Florida), and which controlled for significant differences in baseline characteristics between the HCW and non-HCW groups, showed that the odds of having a positive COVID-19 test were not significantly different for HCW compared to non-HCW, and HCW had lower odds of subsequent hospitalization, and without statistically significant differences in ICU admission compared to non-HCW once they tested positive. The HCW classified as having patient-facing positions had higher and significant odds of a positive COVID-19 test with insignificant differences detected compared to non-patient-facing HCW in outcomes of hospitalization or ICU admission. We found a similar proportion of HCW with a positive COVID-19 test had presenting symptoms of cough, fatigue, diarrhea, loss of appetite, and vomiting while a lower proportion had fever or shortness of breath. We note that we were not able to capture the symptoms of loss of taste and/or smell and that these symptoms may be common especially with mild cases of COVID-19.^[@CR24],\ [@CR25]^

The overall proportion of COVID-19 positive tests in HCW was low and decreased during the study period corresponding with implementation of risk-mitigation measures in our health system such as the recommendations for universal masking and physical distancing but also followed the trend for non-HCW. Several of the previous studies of HCW risk for infection during the COVID-19 pandemic were limited by their sample sizes,^[@CR7]--[@CR9]^ lack of generalizability for healthcare systems that have adequate access to PPE,^[@CR7]--[@CR9]^ methodology relying on self-report,^[@CR12]^ limited ability to adjust for known risk factors of disease susceptibility and progression, ^[@CR7]--[@CR10],\ [@CR12]^ and lacking data to investigate the relative effects of dual exposure of HCW to COVID-19 in the community versus the workplace.^[@CR7]--[@CR10],\ [@CR12]^ The fact that HCW identified as patient facing had a significantly higher odds for SARS-CoV-2 test positivity suggests an increased risk of COVID-19 infection with work exposure. However, it is important to note in our study that over 70% of the HCW group reported an exposure to COVID-19 with 28% reporting exposure to a family member with COVID-19. In our study, we were not able to confirm if the patient-facing HCW were working in patient-facing areas during the 14-day period before the test was ordered when exposure could have occurred, or whether the exposure occurred with or without PPE---both in the workplace or in the community, or the relative contribution of initially prioritizing testing availability to HCW with reported exposures. While the risk to HCW attributed to community spread may not be captured in our available data, the reported exposure risk including the higher proportion of HCW vs. non-HCW reporting exposure to a family member with COVID-19 suggests a degree of community acquisition of infection. A potential contributing factor to community acquisition is that HCW, particularly patient-facing HCW, are less able to follow stay-at-home guidelines or work remotely from home. Indeed, while PPE use is associated with decreased risk of infection from coronavirus,^[@CR26]^ a recent report estimated less than 5% risk to HCW inadvertently exposed to patients not known to be SARS-CoV-2-positive at the time of initial exposure with exposure likely occurring without appropriate PPE^[@CR27]^ suggesting that the work exposure risk may actually be low. However, universal pandemic precautions have been recommended for optimal risk mitigation for HCW.^[@CR28]^

CONCLUSION {#Sec10}
==========

In our analysis of one healthcare system which implemented significant risk-mitigation strategies to prevent the spread of COVID-19 infection, and which controlled for significant baseline differences in HCW compared to non-HCW, the odds for SARS-CoV-2 infection were similar for HCW and non-HCW and HCW had lower odds for COVID-19-related hospitalization. The patient-facing HCW had higher odds of SARS-CoV-2 infection.
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